JPMorgan Chase & Co. decreased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 6.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,156,275 shares of the company's stock after selling 154,534 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.08% of Sanofi worth $103,997,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after buying an additional 33,105 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Sanofi by 408.6% during the third quarter. The Manufacturers Life Insurance Company now owns 160,339 shares of the company's stock valued at $9,244,000 after purchasing an additional 128,811 shares during the last quarter. Benjamin Edwards Inc. bought a new position in Sanofi in the third quarter valued at approximately $991,000. Hilltop Holdings Inc. increased its position in shares of Sanofi by 47.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 10,224 shares of the company's stock worth $589,000 after purchasing an additional 3,313 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Sanofi by 1.0% during the 3rd quarter. HighTower Advisors LLC now owns 88,100 shares of the company's stock worth $5,081,000 after purchasing an additional 848 shares in the last quarter. Institutional investors own 14.04% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on SNY shares. StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $62.50.
Check Out Our Latest Report on SNY
Sanofi Stock Performance
Shares of NASDAQ:SNY traded down $2.64 on Friday, hitting $51.98. The company had a trading volume of 3,162,438 shares, compared to its average volume of 2,285,156. The stock has a 50 day moving average price of $55.38 and a 200 day moving average price of $52.75. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market cap of $131.92 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts expect that Sanofi will post 4.36 EPS for the current year.
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
